Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACE: Proof of Concept Phase I/II Trial of the CXCR2 Antagonist AZD5069, Administered in Combination With Enzalutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03177187 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT03177187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03177187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACE: Proof of Concept Phase I/II Trial of the CXCR2 Antagonist AZD5069, Administered in Combination With Enzalutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 1/2
Overall status
Terminated
Start date
November 13, 2017
Completion date
November 16, 2022
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer